^
Association details:
Evidence:
Evidence Level:
Sensitive: B - Late Trials
Title:

Molecular Predictors of Outcome With Gefitinib in a Phase III Placebo-Controlled Study in Advanced Non–Small-Cell Lung Cancer

Published date:
09/21/2016
Excerpt:
The phase III Iressa Survival Evaluation in Lung Cancer (ISEL) trial compared gefitinib with placebo in 1,692 patients with refractory advanced non–small-cell lung cancer....High EGFR protein expression was present in 264 patients (69.6%), and EGFR-positive patients achieved significantly better survival with gefitinib versus placebo than patients with EGFR protein expression–negative tumors (interaction test P = .049; Fig 3).
DOI:
10.1200/JCO.2006.06.3958
Evidence Level:
Sensitive: C2 – Inclusion Criteria
New
Title:

A Trial of Gefitinib in Combination With BKM120 in Patients With Advanced Non-Small Cell Lung Cancer, With Enrichment for Patients Whose Tumours Harbour Molecular Alterations of PI3K Pathway and Known to Overexpress EGFR

Excerpt:
...- Enrichment Cohort (Patient Group 2 "Pathway Driven Group") Activated PI3K status (Section 7.1) in patients whose tumours are known historically to overexpress EGFR....
Evidence Level:
Sensitive: C3 – Early Trials
New
Title:

Epidermal growth factor receptor messenger RNA expression, gene dosage, and gefitinib sensitivity in non-small cell lung cancer

Excerpt:
Patients with high EGFR mRNA expression (>5.01) had 43% response probability, whereas patients with low EGFR mRNA expression had 8% response probability (P = 0.006). Patients with high EGFR mRNA expression had longer median progression-free (5.3 versus 2.8 months, P = 0.028)...
DOI:
10.1158/1078-0432.CCR-06-0106